Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E J P van Asseldonk

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Diabetes, Obesity & Metabolism|July 22, 2014
The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose toleranceP C M van Poppel, E J P van Asseldonk, J J Holst, et al.
The Netherlands Journal of Medicine|October 8, 2011
Multiple osteolytic bone lesionsE J P van Asseldonk, R G L de Sévaux, U E Flucke, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Diabetes, Obesity & Metabolism|July 22, 2014
The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose toleranceP C M van Poppel, E J P van Asseldonk, J J Holst, et al.
The Netherlands Journal of Medicine|October 8, 2011
Multiple osteolytic bone lesionsE J P van Asseldonk, R G L de Sévaux, U E Flucke, et al.
Pageof 1